> Details

Giorgi, Mariano Anibal [Author]; Caroli, Christian [Author]; Giglio, Norberto Damian [Author]; Micone, Paula [Author]; Aiello, Eleonora [Author]; Vulcano, Cristina [Author]; Blanco, Julia [Author]; Donato, Bonnie [Author]; Quevedo, Joaquin Mould [Author]

Estimation of the cost-effectiveness of apixaban versus vitamin K antagonists in the management of atrial fibrillation in Argentina

Reference
management

Bookmarks

Remove from
bookmarks

Share this on Whatsapp

Close

Bookmarks



You can manage bookmarks using lists, please log in to your user account for this.
  • Media type: E-Article
  • Title: Estimation of the cost-effectiveness of apixaban versus vitamin K antagonists in the management of atrial fibrillation in Argentina
  • Contributor: Giorgi, Mariano Anibal [Author]; Caroli, Christian [Author]; Giglio, Norberto Damian [Author]; Micone, Paula [Author]; Aiello, Eleonora [Author]; Vulcano, Cristina [Author]; Blanco, Julia [Author]; Donato, Bonnie [Author]; Quevedo, Joaquin Mould [Author]
  • imprint: Heidelberg: Springer, 2015
  • Language: English
  • DOI: https://doi.org/10.1186/s13561-015-0052-8
  • ISSN: 2191-1991
  • Keywords: Apixaban ; Warfarin ; Cost-effectiveness ; Novel oral anticoagulants
  • Origination:
  • Footnote: Diese Datenquelle enthält auch Bestandsnachweise, die nicht zu einem Volltext führen.
  • Description: Apixaban, a novel oral anticoagulant which has been approved for the prevention of stroke and systemic embolism in non-valvular atrial fibrillation, reduces both ischemic and haemorrhagic stroke and produces fewer bleedings than vitamin K antagonist warfarin. These clinical results lead to a decrease in health care resource utilization and, therefore, have a positive impact on health economics of atrial fibrillation. The cost-effectiveness of apixaban has been assessed in a variety of clinical settings and countries. However, data from emergent markets, as is the case of Argentina, are still scarce. We performed a cost-effectiveness analysis of apixaban versus warfarin in non-valvular atrial fibrillation (NVAF) in patients suitable for oral anticoagulation in Argentina. A Markov-based model including both costs and effects were used to simulate a cohort of patients with NVAF. Local epidemiological, resource utilization and cost data were used and all inputs were validated by a Delphi Panel of local experts. We adopted the payer's perspective with costs expressed in 2012 US Dollars. The study revealed that apixaban is cost-effective compared with warfarin using a willingness to pay threshold ranging from 1 to 3 per capita Gross Domestic Product (11558 - 34664 USD) with an incremental cost-effectiveness ratio of 786.08 USD per QALY gained. The benefit is primarily a result of the reduction in stroke and bleeding events. The study demonstrates that apixaban is a cost-effective alternative to warfarin in Argentina.
  • Access State: Open Access
  • Rights information: Attribution (CC BY)